Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

SciClone Collaborates with Soligenix on Oral Mucositis Treatment

publication date: Jul 8, 2013
SciClone Pharma has formed a collaboration with Soligenix, a New Jersey clinical-stage biopharma, to develop a personal medicine treatment for oral mucositis. SciClone will grant Soligenix access to its own oral mucositis clinical and regulatory data in return for China rights to SGX942, Soligenix’ novel treatment for the disorder. SciClone is a US company that distributes western drugs in China. Financial details of the pact were not disclosed. More details....

Stock Symbols: (NSDQ: SCLN) (OTCQB: SNGX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China